{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-043277","form_type":"8-K","ticker":"MDAI","cik":"0001833498","company_name":"Spectral AI, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.022520+00:00","generated_at":"2026-05-21T09:57:22.846660+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Spectral AI Q1 net income $2.9M; cash $14.1M; FDA De Novo submission planned H1 2025","bullets":["Q1 2025 R&D revenue $6.7M (+6% YoY); net income $2.9M vs net loss $(3.2)M in Q1 2024.","Net income largely driven by $4.4M non-cash decrease in warrant liability fair value.","Cash improved to $14.1M at March 31, 2025 from $5.2M at Dec 2024.","Debt financing of $15M from Avenue Capital; initial draw $8.5M; also raised $2.7M equity.","Burn Validation Study completed with 164 patients; FY 2025 revenue guidance reiterated at ~$21.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-043277","json":"https://secwatch.observer/filing/0001213900-25-043277.json","markdown":"https://secwatch.observer/filing/0001213900-25-043277.md","text":"https://secwatch.observer/filing/0001213900-25-043277.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833498/000121390025043277/0001213900-25-043277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833498/000121390025043277/ea0242162-8k_spectral.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:57:22.846660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}